肝癌靶向治疗导致肝损伤的应对策略  

Strategies for liver injury caused by hepatocellular carcinoma targeted therapy

作　　者：赵素贤[1] 刘世恒 南月敏[1] Zhao Suxian;Liu Shiheng;Nan Yuemin(Department of Traditional and Western Medical Hepatology,Hebei Medical University Third Hospital,the Key Laboratory of Hepatic Fibrosis Mechanisms of Chronic Liver Diseases in Hebei Province,Hebei International Science and Technology Cooperation Base--Hebei International Joint Research Center for Molecular Diagnosis of Liver Cancer,Shijiazhuang 050051,China)

机构地区：[1]河北医科大学第三医院中西医结合肝病科、河北省慢性肝病肝纤维化研究重点实验室、河北省国际科技合作基地--河北省肝癌分子诊断国际联合研究中心,石家庄050051

出　　处：《中华肝脏病杂志》2023年第11期1129-1132,共4页Chinese Journal of Hepatology

基　　金：河北省第四批高端人才基金;2021年政府资助临床医学人才培养项目。

摘　　要：原发性肝细胞癌恶性程度高,起病隐匿且发展迅速,严重威胁人类的生命和健康。随着对肿瘤分子学特征研究的不断深入,分子靶向药物已成为晚期肝癌患者的重要治疗手段。肝损伤是靶向药物常见的不良反应之一,需引起重视。现主要从肝癌靶向药物导致肝损伤的发生情况、机制、危险因素、诊断和治疗等方面做简要阐述,以期为肝癌患者临床安全应用靶向药物提供参考。Primary hepatocellular carcinoma has a high degree of malignancy,insidious onset,and rapid progression that seriously threatens human life and health.With the continuous deepening of the study of the molecular characteristics of tumors,molecular targeted drugs have become an important treatment method for patients with advanced liver cancer.Liver injury is one of the common adverse reactions of targeted drugs,which needs to be paid attention to.This paper mainly briefly expounds on the occurrence condition,mechanism,risk factors,diagnosis,and treatment of liver injury caused by hepatocellular carcinoma targeted therapy in order to provide a reference for the safe clinical application of targeted drugs.

关 键 词：肝细胞癌 靶向治疗 药物性肝损伤 

分 类 号：R735.7[医药卫生—肿瘤]